Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

Sobi to advance Gamifant in interferon-gamma-driven sepsis based on EMBRACE topline data: Stockholm Friday, January 9, 2026, 11:00 Hrs [IST] Sobi, a global biopharma company, anno ...

Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...

On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells ...

Using data from Crunchbase and PitchBook, TechCrunch tracked down the VC-backed startups that became unicorns so far this ...

Scientists are testing the ancient herb borage to see which healing claims hold up and where modern evidence still falls ...

While visual training will likely continue to be a productive part of treatment for people with hemianopia, the EPFL study ...

Inovor Technologies is blending sovereign design with global partnerships to redefine Australia’s satellite manufacturing ...

While many non-alcoholic drinks want to replicate the taste of a tipple, Sentia wants to replicate the effects ...

Alzheimer’s disease has long been the nightmare diagnosis that medicine could slow at best, not stop. Now a wave of ...

In the ruins of Chernobyl’s shattered reactors, something unexpected has taken root. Thick black mats of mold are thriving where radiation levels would shred human DNA, turning abandoned nuclear sites ...